2023
Scaling up evidence-based approaches to tuberculosis screening in prisons
Charalambous S, Velen K, Rueda Z, Croda J, Herce M, Shenoi S, Altice F, Muyoyeta M, Telisinghe L, Grandjean L, Keshavjee S, Andrews J. Scaling up evidence-based approaches to tuberculosis screening in prisons. The Lancet Public Health 2023, 8: e305-e310. PMID: 36780916, DOI: 10.1016/s2468-2667(23)00002-6.Commentaries, Editorials and LettersConceptsIncidence of tuberculosisCase-finding strategyHigh tuberculosis burdenMinistry of HealthEvidence-based approachTuberculosis burdenTreatment cascadeTuberculosis screeningTuberculosis notificationsTuberculosis diagnosisGeneral populationCare programDiagnostic strategiesTuberculosisEvidence baseSystematic screeningHigh rateIncidenceScreeningSetting
2018
Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review
Kinner SA, Snow K, Wirtz AL, Altice FL, Beyrer C, Dolan K. Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review. Journal Of Adolescent Health 2018, 62: s18-s26. PMID: 29455713, PMCID: PMC7413042, DOI: 10.1016/j.jadohealth.2017.09.030.Peer-Reviewed Original ResearchConceptsHepatitis CHepatitis BRelative riskOlder prisonersGlobal prevalencePrevalence estimatesSystematic reviewPrevalence of HIVAge-specific prevalence estimatesAge-specific prevalenceIncidence of infectionActive tuberculosisPooled prevalenceLow prevalenceHIVPrevalenceInfectionYoung adultsTuberculosisAge categoriesIncarcerated populationsAYAsIncarcerated adolescentsIncarcerated peopleCustodial settings
2017
Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic
Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic. International Journal Of Drug Policy 2017, 48: 44-53. PMID: 28800420, PMCID: PMC5603251, DOI: 10.1016/j.drugpo.2017.05.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMedication-assisted treatment programTB test resultsTwelve-month retentionCare delivery systemCorrelates of retentionEvidence-based strategiesTB patientsMultivariable analysisOpioid dependenceAgonist treatmentHIV transmissionClinical recordsHIV epidemicOAT programsPatient retentionHigher dosingHigh dosesTreatment programPatientsSurvival analysis methodsDosingTuberculosisElectronic monitoring systemTreatment
2016
Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis
Rich JD, Beckwith CG, Macmadu A, Marshall BDL, Brinkley-Rubinstein L, Amon JJ, Milloy MJ, King MRF, Sanchez J, Atwoli L, Altice FL. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. The Lancet 2016, 388: 1103-1114. PMID: 27427452, PMCID: PMC5504684, DOI: 10.1016/s0140-6736(16)30379-8.Peer-Reviewed Original ResearchConceptsClinical careCommunity-based health careJail settingsHealth careDelivery of careCommunity-based treatmentProvision of treatmentHIV/AIDSPrison health careHepatitis BViral hepatitisMiddle-income countriesC virusClinical managementHigh-income countriesGeneral populationMedical careMental illnessInfectious diseasesOptimal deliverySubstance useCareTransmissible diseasesHIVTuberculosisThe perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stöver H, Dolan K, Vickerman P. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. The Lancet 2016, 388: 1228-1248. PMID: 27427455, PMCID: PMC5087988, DOI: 10.1016/s0140-6736(16)30856-x.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyHepatitis C virusIncident tuberculosis casesAgonist therapyC virusTuberculosis casesHIV transmissionEECA countriesAntiretroviral therapy coverageHIV transmission riskNew HIV infectionsInjection of opioidsTransmission of HIVSecondary preventionHIV infectionHIV incidenceSyringe programsHIVDrug useLarge burdenTransmission riskTherapyTuberculosisDrugsHigh levelsGlobal burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees
Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA, Courtney R, McKee M, Amon JJ, Maher L, Hellard M, Beyrer C, Altice FL. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet 2016, 388: 1089-1102. PMID: 27427453, DOI: 10.1016/s0140-6736(16)30466-4.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusViral hepatitisChronic hepatitis B virusBurden of HIVOpioid agonist therapyPrevalence of HIVTreatment of HIVIncarceration of peopleComprehensive literature searchAgonist therapyActive tuberculosisHIV transmissionC virusB virusGlobal burdenPrevention interventionsGeneral populationGlobal epidemiologyHIVDrug useTuberculosisLiterature searchLarge-scale outbreaksHepatitisPrevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners
Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, Moazen B, Wirtz AL, Verster A, Altice FL. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. The Lancet 2016, 388: 1115-1126. PMID: 27427456, DOI: 10.1016/s0140-6736(16)30769-3.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusC virusB virusOpioid agonist therapySecondary prevention strategiesBlood-borne infectionsPrevalence of HIVOpioid use disorderPrevention of transmissionPublic health systemAgonist therapyEffective treatmentGeneral populationUse disordersPrevention strategiesPrisoner healthHealth systemInfectionHIVVirusTuberculosisAbsence of alternativesTherapyRisk environmentUndiagnosed pulmonary tuberculosis among prisoners in Malaysia: an overlooked risk for tuberculosis in the community
Al-Darraji HA, Altice FL, Kamarulzaman A. Undiagnosed pulmonary tuberculosis among prisoners in Malaysia: an overlooked risk for tuberculosis in the community. Tropical Medicine And International Health 2016, 21: 1049-1058. PMID: 27197601, DOI: 10.1111/tmi.12726.Peer-Reviewed Original ResearchGeneXpert MTB/RIFCase-finding strategyActive TBMTB/RIFTB treatmentMalaysia's largest prisonUndiagnosed pulmonary tuberculosisActive tuberculosis casesOlder age groupsLargest prisonPulmonary tuberculosisHIV infectionTuberculosis casesHigh prevalenceSputum samplesSmear microscopyClinical informationAverage ageCulture resultsAge groupsScreening studyComplete dataHIVRegression analysisTuberculosis
2014
Latent tuberculosis infection screening in foreign-born populations: a successful mobile clinic outreach model.
Morano JP, Zelenev A, Walton MR, Bruce RD, Altice FL. Latent tuberculosis infection screening in foreign-born populations: a successful mobile clinic outreach model. American Journal Of Public Health 2014, 104: 1508-15. PMID: 24922157, PMCID: PMC4103248, DOI: 10.2105/ajph.2014.301897.Peer-Reviewed Original ResearchConceptsLatent tuberculosis infectionTuberculin skin testTuberculosis infectionActive tuberculosisLTBI prevalenceSkin testRisk factorsScreening programHeroin useEligibility criteriaUnstable housingUninsured populationMedical surveyHealth insuranceMarijuana useOutreach modelInfectionRelevant correlatesInterpersonal violenceForeign-born populationNew HavenUrban settingsPopulationTuberculosisPrevalence
2013
Tuberculosis screening in a novel substance abuse treatment center in Malaysia: Implications for a comprehensive approach for integrated care
Al-Darraji HA, Wong KC, Yeow DG, Fu JJ, Loeliger K, Paiji C, Kamarulzaman A, Altice FL. Tuberculosis screening in a novel substance abuse treatment center in Malaysia: Implications for a comprehensive approach for integrated care. Journal Of Substance Use And Addiction Treatment 2013, 46: 144-149. PMID: 24074846, PMCID: PMC5189907, DOI: 10.1016/j.jsat.2013.08.023.Peer-Reviewed Original ResearchConceptsLatent TB infectionTuberculin skin testingDrug treatment centersSubstance abuse treatment centersTreatment centersKey high‐risk groupsVoluntary drug treatment centresCross-sectional convenience surveyHigh-risk groupComplex treatment needsArrest/incarcerationActive diseaseTB infectionTB screeningTST positivitySkin testingRisk groupsTreatment needsHeroin useStandardized questionnaireTreatment entryIntegrated careTreatment programTuberculosisPrevalenceImplementing methadone maintenance treatment in prisons in Malaysia
Wickersham JA, Marcus R, Kamarulzaman A, Zahari MM, Altice FL. Implementing methadone maintenance treatment in prisons in Malaysia. Bulletin Of The World Health Organization 2013, 91: 124-129. PMID: 23554524, PMCID: PMC3605007, DOI: 10.2471/blt.12.109132.Peer-Reviewed Original ResearchConceptsDose of methadoneMMT programHIV infectionHuman immunodeficiency virus (HIV) infectionMethadone maintenance treatment programDaily oral doseImmunodeficiency virus infectionMethadone maintenance treatmentMaintenance treatment programHarm reduction strategiesMinistry of HealthAdequate dosingOral doseMaintenance treatmentMethadone treatmentStandard operating proceduresMMT clientsVirus infectionTreatment programMethadoneOngoing educationInfectionDosePhase 3Tuberculosis
2012
Isoniazid preventive therapy in correctional facilities: a systematic review [Review article]
Al-Darraji HA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in correctional facilities: a systematic review [Review article]. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 871-879. PMID: 22410101, DOI: 10.5588/ijtld.11.0447.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIPT initiationPreventive therapySystematic reviewHuman immunodeficiency virus statusCompletion ratesPrevalent adverse reactionsCorrectional facilitiesIPT effectivenessTreatment interruptionActive tuberculosisViral hepatitisMiddle-income countriesTB controlAdverse reactionsRisk factorsVirus statusEligible studiesCommunity settingsTuberculosisLow-income countriesMajor causeJail settingsAdverse effectsInternational recommendationsSurvival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa
Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. PLOS ONE 2012, 7: e31786. PMID: 22412840, PMCID: PMC3295798, DOI: 10.1371/journal.pone.0031786.Peer-Reviewed Original ResearchConceptsXDR-TB patientsDrug-resistant tuberculosisRetrospective case-control studyXDR-TB casesCommunity-based hospitalCase-control studyGlobal public healthHIV coinfectionMicrobiological correlatesModifiable factorsAvailable interventionsRural South AfricaControl studyPatientsTuberculosisPublic healthSurvivorsSurvivalDaysHospitalMortality